CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Jefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepower

Positive
AI Analysis

Summary

Jefferies resumed coverage of GSK with a 'buy' rating and 30% upside price target, citing the company's oncology pipeline strength.

Importance:4/10
Sentiment:
0.70
analyst_coverageoncologyequity_ratingprice_target
Related Companies

Read the original article

Published by yahoo_finance on July 17, 2026 2:30 PM

Read Original